These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 17322538

  • 1. Clairvoyance or reliable prediction of the future?
    van Zandwijk N, van de Vijver MJ.
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract] [Full Text] [Related]

  • 2. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE, Ramalingam SS.
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract] [Full Text] [Related]

  • 3. NSCLC drug targets acquire new visibility.
    Friedrich MJ.
    J Natl Cancer Inst; 2011 Mar 02; 103(5):366-7. PubMed ID: 21357596
    [No Abstract] [Full Text] [Related]

  • 4. Personalized medicine and inhibition of EGFR signaling in lung cancer.
    Gazdar AF.
    N Engl J Med; 2009 Sep 03; 361(10):1018-20. PubMed ID: 19692681
    [No Abstract] [Full Text] [Related]

  • 5. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
    Ji Y, Schwartz J, Hartford A, Ramsey J, Phillips J, Verschraegen C.
    JAMA Oncol; 2015 Sep 03; 1(6):838-40. PubMed ID: 26181671
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J, Palmer DH, Rea DW, Hussain SA.
    Anticancer Agents Med Chem; 2009 Jun 03; 9(5):569-75. PubMed ID: 19519298
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
    Costa DB, Schumer ST, Tenen DG, Kobayashi S.
    J Clin Oncol; 2008 Mar 01; 26(7):1182-4; author reply 1184-6. PubMed ID: 18309959
    [No Abstract] [Full Text] [Related]

  • 13. Is FISH floating or still swimming in the lung cancer ocean?
    Cappuzzo F, Camidge DR, Varella-Garcia M.
    Ann Oncol; 2011 Mar 01; 22(3):493-499. PubMed ID: 21292645
    [No Abstract] [Full Text] [Related]

  • 14. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
    Clin Lung Cancer; 2004 May 01; 5(6):331-2. PubMed ID: 15217530
    [No Abstract] [Full Text] [Related]

  • 15. [Mechanism of action and preclinical development of afatinib].
    Diz Taín P, González AL, García-Palomo A.
    Med Clin (Barc); 2016 Apr 01; 146 Suppl 1():7-11. PubMed ID: 27426242
    [Abstract] [Full Text] [Related]

  • 16. Medical treatment of non-small-cell lung cancer.
    Buter J, Giaccone G.
    Ann Oncol; 2005 Apr 01; 16 Suppl 2():ii229-32. PubMed ID: 15958463
    [No Abstract] [Full Text] [Related]

  • 17. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
    Saijo N.
    Nat Rev Clin Oncol; 2010 Nov 01; 7(11):618-9. PubMed ID: 20981125
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.